Yu-Feng Chen
Overview
Explore the profile of Yu-Feng Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
92
Citations
949
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen Y, Ho H, Tseng C, Chen Y, Wang S, Shieh J, et al.
Sci Rep
. 2024 Jul;
14(1):17495.
PMID: 39079980
Short-chain fatty acids (SCFAs) have been proposed to have anti-inflammatory effects and improve immune homeostasis. We aimed to examine the effects of SCFAs on skin phenotype, systemic inflammation, and gut...
2.
Mu Y, Chang K, Chen Y, Yan K, Wang C, Hua Q
J Biol Methods
. 2024 Jul;
11:e99010010.
PMID: 38988499
Alzheimer's disease (AD) is a serious dementia afflicting aging population and is characterized by cognitive decline, amyloid-β plaques, and neurofibrillary tangles. AD substantially impairs the life quality of the victims...
3.
Chen Y, Zeng W
Int J Ophthalmol
. 2024 May;
17(5):963-968.
PMID: 38766345
Although selective laser trabeculoplasty (SLT) is a recognized method for the treatment of glaucoma, the exact changes in the target tissue and mechanism for its intraocular pressure lowing effect are...
4.
Dai C, Tian J, Chen Y, Ni Y, Cui L, Cao H, et al.
Biotechnol J
. 2024 Mar;
19(3):e2300637.
PMID: 38472092
The aldo-keto reductase (AKR) KdAKR from Kluyvermyces dobzhanskii can reduce t-butyl 6-chloro-(5S)-hydroxy-3-oxohexanoate ((5S)-CHOH) to t-butyl 6-chloro-(3R,5S)-dihydroxyhexanoate ((3R,5S)-CDHH), which is the key chiral intermediate of rosuvastatin. Herein, a computer-aided design that...
5.
Chen Y, Gong W, Zhao Q, Liu C
J Asian Nat Prod Res
. 2024 Mar;
26(7):788-794.
PMID: 38469737
Two previously undescribed iridoid glycosides, 6'--trans-feruloyl-(4,6)-3,4-dihydro-3-ethoxypaederoside () and 6'--trans-caffeoyl-(4,6)-3,4-dihydro-2'--3-paederoside (), were isolated from the 90% EtOH extract of the air dried aerial parts of . Structural elucidation of all the...
6.
Wu J, Wu J, Fu Y, Ou X, Li S, Zhang Z, et al.
Ann Surg Oncol
. 2024 Feb;
31(5):3073-3083.
PMID: 38316732
Background: Combination treatment with transcatheter arterial chemoembolization (TACE), lenvatinib, and anti-programmed death-1 (anti-PD-1) antibodies (triple therapy) has a high rate of tumor response and converted resection for initially unresectable hepatocellular...
7.
Wu X, Yang L, Chen Y, Chen Z, Lu H, Shen X, et al.
EClinicalMedicine
. 2024 Jan;
67:102367.
PMID: 38169778
Background: The synergistic effect of locoregional therapy in combination with systemic therapy as a conversion therapy for unresectable hepatocellular carcinoma (uHCC) is unclear. The purpose of this study was to...
8.
Tseng C, Wang W, Chen Y, Chen Y
J Dent Sci
. 2023 Oct;
18(4):1889-1891.
PMID: 37799872
No abstract available.
9.
Wu J, Zhang Z, Zhou J, Ke J, Bai Y, Chen Y, et al.
Liver Cancer
. 2023 Sep;
12(3):229-237.
PMID: 37767067
Introduction: The actual rate of conversion surgery and its prognostic advantages remain unclear. This study aimed to assess the outcomes of salvage surgery after conversion therapy with triple therapy (transcatheter...
10.
Chen Y, Mao M, Zhu G, Sun C, Zhao J, He H, et al.
BMC Complement Med Ther
. 2023 Sep;
23(1):334.
PMID: 37735652
Background: Tui Na (Chinese massage) is a relatively simple, inexpensive, and non-invasive intervention, and has been used to treat stroke patients for many years in China. Tui Na acts on...